COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
Related Experiment Video
Updated: Dec 21, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Georg Härter1, Christoph D Spinner2, Julia Roider3,4
1Medicover Ulm MVZ, Münsterplatz 6, 89073, Ulm, Germany. ghaerter@gmx.de.
Insights
People living with HIV (PLWH) on antiretroviral treatment (ART) experienced mild COVID-19 outcomes. This study found no excess mortality in PLWH with suppressed viral loads, suggesting ART may be protective.
Area of Science:
- Infectious Diseases
- Virology
- Immunology
Background:
- Limited data exists on COVID-19 outcomes for people living with human immunodeficiency virus (PLWH).
- This case series examines symptoms and outcomes in 33 PLWH patients diagnosed with COVID-19.
Purpose of the Study:
- To investigate the clinical presentation and outcomes of COVID-19 in individuals living with HIV.
- To assess potential excess morbidity and mortality in this population during the SARS-CoV-2 pandemic.
Main Methods:
- Retrospective analysis of anonymized patient data.
- Inclusion of demographic, HIV-associated parameters, symptoms, and outcome data.
- Focus on patients on antiretroviral treatment (ART).
Main Results:
- 91% of patients recovered from COVID-19, with 76% experiencing mild cases.
- Mortality rate was 9% (3 out of 32 patients with documented outcomes).
- All patients were on ART, with many on tenofovir-containing regimens or darunavir.
Conclusions:
- Preliminary findings do not indicate excess morbidity or mortality for symptomatic COVID-19 PLWH with viral suppression on ART.
- SARS-CoV-2 infection can occur in patients on boosted darunavir-based and/or tenofovir-containing ART.
Introduction:
Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population.
Methods:
Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome.
Results:
Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir.
Conclusions:
This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.
Related Concept Videos
Sexually Transmitted Infections
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Retrovirus Life Cycles

